Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation

Abstract

Aim: To evaluate the role of sequential therapy and Lactobacillus reuteri (L. reuteri) supplementation, in the eradication treatment of Helicobacter pylori (H. pylori).

Methods: H. pylori infection was diagnosed in 90 adult dyspeptic patients. Patients were excluded if previously treated for H. pylori infection or if they were taking a proton pump inhibitor (PPI), H2-receptor antagonist or antibiotics. Patients were assigned to receive one of the following therapies: (1) 7-d triple therapy (PPI plus clarithromycin and amoxicillin or metronidazole) plus L. reuteri supplementation during antibiotic treatment; (2) 7-d triple therapy plus L. reuteri supplementation after antibiotic treatment; (3) sequential regimen (5-d PPI plus amoxicillin therapy followed by a 5-d PPI, clarithromycin and tinidazole) plus L. reuteri supplementation during antibiotic treatment; and (4) sequential regimen plus L. reuteri supplementation after antibiotic treatment. Successful eradication therapy was defined as a negative urea breath test at least 4 wk following treatment.

Results: Ninety adult dyspeptic patients were enrolled, and 83 (30 male, 53 female; mean age 57 ± 13 years) completed the study. Nineteen patients were administered a 7-d triple treatment: 11 with L. reuteri supplementation during and 8 after therapy. Sixty-four patients were administered a sequential regimen: 32 with L. reuteri supplementation during and 32 after therapy. The eradication rate was significantly higher in the sequential group compared with the 7-d triple regimen (88% vs 63%, P = 0.01). No difference was found between two types of PPI. No difference in eradication rates was observed between patients submitted to L. reuteri supplementation during or after antibiotic treatment. Compliance with therapy was excellent in all patients. No difference in adverse effects was observed between the different antibiotic treatments and between patients submitted to L. reuteri supplementation during and after antibiotic treatment. There was a low incidence of adverse effects in all groups of patients with sequential therapy, probably due to the presence of the L. reuteri supplementation.

Conclusion: The sequential treatment regimen achieved a significantly higher eradication rate of H. pylori compared with standard 7-d regimen. L. reuteri supplementation could reduce the frequency and the intensity of antibiotic-associated side-effects.

Keywords: Eradication; Gastritis; Helicobacter pylori; Lactobacillus reuteri; Probiotics; Sequential therapy.

Figure 1

Helicobacter pylori eradication rate in the following groups of patients. 1: 10-d sequential therapy plus Lactobacillus reuteri (L. reuteri) post therapy; 2: 10-d sequential therapy plus L. reuteri during therapy; 3: 10-d sequential therapy; 4: 7-d standard triple therapy plus L. reuteri post therapy; 5: 7-d standard triple therapy plus L. reuteri during therapy; 6: 7-d standard triple therapy. The eradication rate was significantly higher in the sequential group compared with the 7-d triple therapy group (88% vs 63%, P = 0.01). No difference was found between patients submitted to L. reuteri supplementation during or after antibiotic treatment.